Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2017 Dec;12(6):517–525. doi: 10.4103/1735-5362.217432

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright: © 2017 Research in Pharmaceutical Sciences

This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as the author is credited and the new creations are licensed under the identical terms.

PMC Copyright notice

Fig. 2 — Water-soluble tetrazolium-1 (WST-1, cell viability assay) results of capecitabine, oxaliplatin, and 17-AAG in double combinations (2 × IC₅₀, 1 × IC₅₀, 0.5 × IC₅₀, and 0.25 × IC₅₀) and triple combinations (1 × IC₅₀, 0.5 × IC₅₀, and 0.25 × IC₅₀) at different concentrations of each drug on (A), HCT-116 and (B), HT-29 cells. Data are presented as mean ± standard deviation. (17-AAG), 17-allylamino-17-demethoxygeldanamycin; (Cap), capecitabine; (Ox), oxaliplatin. * Significant differences between double combination compared with single treatments of each individual drug (P < 0.05). ** Significant differences of triple drug treated cases in compared to double combinations of each drugs (P < 0.05).